OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

October 23rd 2020

Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.

Dr. Ahn on the Evolution of Targetable Alterations in CRC

October 23rd 2020

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

Dr. Mahal on the Potential Role of Race in Prostate Cancer Disparities

October 23rd 2020

Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.

Dr. Baskin on Treatment Considerations in Prostate Cancer

October 23rd 2020

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

Dr. Skarbnik on Selecting Between BTK Inhibitors in MCL

October 23rd 2020

Alan P. Z. Skarbnik, MD, discusses factors to consider in selecting between BTK inhibitors in mantle cell lymphoma.

Dr. Mesa on Management Strategies for MPNs

October 23rd 2020

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Dr. Awan on Treatment Options in the First Relapsed Setting of CLL

October 23rd 2020

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

Dr. Azad on the Significance of the PROfound Trial in mCRPC

October 23rd 2020

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Dr. Kantoff on Future Research Efforts in Prostate Cancer

October 23rd 2020

Philip W. Kantoff, MD, discusses future research efforts in prostate cancer.

Dr. Shore on Unmet Needs in Nonmetastatic CRPC

October 23rd 2020

Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.

Dr. Petrylak on Future Research in Prostate Cancer

October 22nd 2020

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

Dr. Nagle on the Evolution of Daratumumab Administration in Multiple Myeloma

October 22nd 2020

Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.

Dr. Tolaney on Data With Trastuzumab Deruxtecan in HER2+ Breast Cancer Brain Metastases

October 22nd 2020

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

Dr. Grothey on Combination Therapies with Regorafenib and TAS-102 in CRC

October 22nd 2020

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Skarbnik on Treatment Considerations in CLL

October 22nd 2020

Alan P. Z. Skarbnik, MD, discusses treatment considerations in chronic lymphocytic leukemia.

Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas

October 22nd 2020

Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.

Dr. Abraham on Remaining Questions With Pexidartinib in TGCT

October 21st 2020

John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.

Dr. D’Amato on the Limitations of Liquid Biopsy in Sarcoma

October 21st 2020

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Dr. Maki on the Utility of IDH1/2 Inhibitors in Chondrosarcoma

October 21st 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.

Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRC

October 21st 2020

Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.